Veterinary Medicines

Spizobactin 1,500,000 IU / 250 mg chewable tablets for dogs

Authorised
  • Metronidazole
  • Spiramycin
Download as PDF

Product identification

Medicine name:
Spizobactin 1,500,000 IU / 250 mg chewable tablets for dogs
Spizobactin vet 1500000 IU / 250 mg purutabletti
Active substance:
  • Metronidazole
  • Spiramycin
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Metronidazole
    250.00
    milligram(s)
    /
    1.00
    Tablet
  • Spiramycin
    357.14
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01RA04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:
  • (ID10) 100 Chewable tablets: cardboard box with 10 cardboard boxes each with 1 Blister (PolyVinyl Chloride, PolyEthylene, PolyVinylidene Chloride) with 10 Chewable tablets, closed with foil (Aluminium)
  • (ID3) 30 Chewable tablets: cardboard box with 3 Blisters (PolyVinyl Chloride, PolyEthylene, PolyVinylidene Chloride) each with 10 Chewable tablets, closed with foil (Aluminium)
  • (ID2) 20 Chewable tablets: cardboard box with 2 Blisters (PolyVinyl Chloride, PolyEthylene, PolyVinylidene Chloride) each with 10 Chewable tablets, closed with foil (Aluminium)
  • (ID1) 10 Chewable tablets: cardboard box with 1 Blister (PolyVinyl Chloride, PolyEthylene, PolyVinylidene Chloride) with 10 Chewable tablets, closed with foil (Aluminium)
  • (ID11) 100 Chewable tablets: cardboard box with 1 Blister (PolyVinyl Chloride, PolyEthylene, PolyVinylidene Chloride) with 10 Chewable tablets, closed with foil (Aluminium)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Le Vet. Beheer B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 34488
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0171/002
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 15/02/2022
Download
Finnish (PDF)
Published on: 28/11/2025
Download

Combined File of all Documents

English (PDF)
Published on: 22/03/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 28/11/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."